Back to search
FDAFDA · Food and drugs·Recall number D-1249-2019

Losartan Potassium Tablets USP 50 mg 50 tablets (5x10) Unit Dose Rx Only NDC 50268-517-15 Manufactured for: AvKARE Inc. Pulaski, TN 38478

Published May 8, 2019 · Recall initiated: April 24, 2019

Summary

FDA records drug Class II recall D-1249-2019, published May 8, 2019 and initiated April 24, 2019. Recalling firm: AVKARE Inc.; Status: Ongoing; Reported quantity: 1438 cartons (71,900 tablets); Lot: Lot: 20121 Exp. 6/30/2019. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Ongoing — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

CGMP Deviations: FDA lab confirmed presence of an impurity, N-Methylnitrosobutyric acid (NMBA) in the finished product above the interim acceptable daily intake level of 0.96 parts per million.

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
AVKARE Inc.
Distributor
Nationwide
Lot
Lot: 20121 Exp. 6/30/2019
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Losartan Potassium Tablets USP 50 mg 50 tablets (5x10) Unit Dose Rx Only NDC 50268-517-15 Manufactured for: AvKARE Inc. Pulaski, TN 38478 recalled?

Yes. FDA published recall D-1249-2019 on May 8, 2019. Reported hazard: CGMP Deviations: FDA lab confirmed presence of an impurity, N-Methylnitrosobutyric acid (NMBA) in the finished product above the interim acceptable daily intake level of 0.96 parts per million.

What should I do if I have this product?

Voluntary: Firm initiated · Letter